



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/995,529	11/26/2001	Jeffry D. Watkins	P-IX 4976	2007

21971 7590 09/26/2006

WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO, CA 94304-1050

EXAMINER

RAWLINGS, STEPHEN L

ART UNIT PAPER NUMBER

1643

DATE MAILED: 09/26/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No. 09/995,529	Applicant(s) WATKINS ET AL.	
Examiner Stephen L. Rawlings, Ph.D.	Art Unit 1643	

Status of Application: _____

(3) Larry Helms.

(4) *Megan Jamroz and MaryAnn Stretch.*

Time:

☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Part I.

written description; new matter; enablement

89-120

Xu et al. *Hybridoma*. 2000 Oct;19(5):375-85.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner proposed an Examiner's amendment and explained the reasons the amendment would obviate the issue of record, noting in particular the need to differentiate between the claimed invention and antibodies disclosed by the prior art. Applicant's representatives declined to authorize entry of the proposed amendment, indicating that they would prefer to file an After-Final Amendment but suggested that they would use the proposed amendment as a guide in the preparation of their amendment..



STEPHEN L. RAWLINGS, PH.D.
PRIMARY EXAMINER